| FXR is a molecular target for the effects of vertical sleeve gastrectomy KK Ryan, V Tremaroli, C Clemmensen, P Kovatcheva-Datchary, ... Nature 509 (7499), 183-188, 2014 | 1011 | 2014 |
| Animal models of obesity and diabetes mellitus M Kleinert, C Clemmensen, SM Hofmann, MC Moore, S Renner, ... Nature Reviews Endocrinology 14 (3), 140-162, 2018 | 795 | 2018 |
| Blood BDNF concentrations reflect brain-tissue BDNF levels across species AB Klein, R Williamson, MA Santini, C Clemmensen, A Ettrup, M Rios, ... International Journal of Neuropsychopharmacology 14 (3), 347-353, 2011 | 769 | 2011 |
| A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents B Finan, B Yang, N Ottaway, DL Smiley, T Ma, C Clemmensen, ... Nature medicine 21 (1), 27-36, 2015 | 606 | 2015 |
| The new biology and pharmacology of glucagon TD Müller, B Finan, C Clemmensen, RD DiMarchi, MH Tschöp Physiological reviews 97 (2), 721-766, 2017 | 349 | 2017 |
| Alternatively activated macrophages do not synthesize catecholamines or contribute to adipose tissue adaptive thermogenesis K Fischer, HH Ruiz, K Jhun, B Finan, DJ Oberlin, V Van Der Heide, ... Nature medicine 23 (5), 623-630, 2017 | 326 | 2017 |
| Gut-brain cross-talk in metabolic control C Clemmensen, TD Müller, SC Woods, HR Berthoud, RJ Seeley, ... Cell 168 (5), 758-774, 2017 | 276 | 2017 |
| Unimolecular polypharmacy for treatment of diabetes and obesity MH Tschöp, B Finan, C Clemmensen, V Gelfanov, D Perez-Tilve, ... Cell metabolism 24 (1), 51-62, 2016 | 229 | 2016 |
| Will the COVID-19 pandemic worsen the obesity epidemic? C Clemmensen, MB Petersen, TIA Sørensen Nature Reviews Endocrinology 16 (9), 469-470, 2020 | 213 | 2020 |
| Chemical hybridization of glucagon and thyroid hormone optimizes therapeutic impact for metabolic disease B Finan, C Clemmensen, Z Zhu, K Stemmer, K Gauthier, L Müller, ... Cell 167 (3), 843-857. e14, 2016 | 182 | 2016 |
| Anti-obesity therapy: from rainbow pills to polyagonists TD Müller, C Clemmensen, B Finan, RD DiMarchi, MH Tschöp Pharmacological reviews 70 (4), 712-746, 2018 | 165 | 2018 |
| GLP-1/glucagon receptor co-agonism for treatment of obesity MA Sánchez-Garrido, SJ Brandt, C Clemmensen, TD Müller, RD DiMarchi, ... Diabetologia 60, 1851-1861, 2017 | 157 | 2017 |
| Reappraisal of GIP pharmacology for metabolic diseases B Finan, TD Müller, C Clemmensen, D Perez-Tilve, RD DiMarchi, ... Trends in Molecular Medicine 22 (5), 359-376, 2016 | 152 | 2016 |
| GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet C Clemmensen, J Chabenne, B Finan, L Sullivan, K Fischer, D Küchler, ... Diabetes 63 (4), 1422-1427, 2014 | 151 | 2014 |
| Exercise increases circulating GDF15 in humans M Kleinert, C Clemmensen, KA Sjøberg, CS Carl, JF Jeppesen, ... Molecular metabolism 9, 187-191, 2018 | 139 | 2018 |
| The GPCR, class C, group 6, subtype A (GPRC6A) receptor: from cloning to physiological function C Clemmensen, S Smajilovic, P Wellendorph, H Bräuner‐Osborne British journal of pharmacology 171 (5), 1129-1141, 2014 | 118 | 2014 |
| Plasma metabolome profiling of resistance exercise and endurance exercise in humans T Morville, RE Sahl, T Moritz, JW Helge, C Clemmensen Cell reports 33 (13), 2020 | 114 | 2020 |
| Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice S Jall, S Sachs, C Clemmensen, B Finan, F Neff, RD DiMarchi, ... Molecular metabolism 6 (5), 440-446, 2017 | 109 | 2017 |
| Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases C Clemmensen, B Finan, TD Mueller, RD DiMarchi, MH Tschöp, ... Nature Reviews Endocrinology 15 (2), 90-104, 2019 | 105 | 2019 |
| Divergent effects of resistance and endurance exercise on plasma bile acids, FGF19, and FGF21 in humans T Morville, RE Sahl, SAJ Trammell, JS Svenningsen, MP Gillum, ... JCI insight 3 (15), 2018 | 97 | 2018 |
Matthias TschöpHelmholtz Zentrum München在 helmholtz-muenchen.de 的电子邮件经过验证
